JP2018534301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534301A5 JP2018534301A5 JP2018523432A JP2018523432A JP2018534301A5 JP 2018534301 A5 JP2018534301 A5 JP 2018534301A5 JP 2018523432 A JP2018523432 A JP 2018523432A JP 2018523432 A JP2018523432 A JP 2018523432A JP 2018534301 A5 JP2018534301 A5 JP 2018534301A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- och
- ocf
- sch
- group selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 7
- -1 Morphorinyl Chemical group 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 claims 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical group C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 102000000795 Galectin 1 Human genes 0.000 claims 1
- 108010001498 Galectin 1 Proteins 0.000 claims 1
- 102000000802 Galectin 3 Human genes 0.000 claims 1
- 108010001517 Galectin 3 Proteins 0.000 claims 1
- 102000007563 Galectins Human genes 0.000 claims 1
- 108010046569 Galectins Proteins 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15193657 | 2015-11-09 | ||
| EP15193657.2 | 2015-11-09 | ||
| EP16172358 | 2016-06-01 | ||
| EP16172358.0 | 2016-06-01 | ||
| PCT/EP2016/076918 WO2017080973A1 (en) | 2015-11-09 | 2016-11-08 | 1,1 '-sulfanediyl-di-beta-d-galactopyranosides as inhibitors of galectins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534301A JP2018534301A (ja) | 2018-11-22 |
| JP2018534301A5 true JP2018534301A5 (enExample) | 2021-02-12 |
| JP6892859B2 JP6892859B2 (ja) | 2021-06-23 |
Family
ID=57281206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018523432A Expired - Fee Related JP6892859B2 (ja) | 2015-11-09 | 2016-11-08 | 新規ガラクトシドによるガレクチン阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10730902B2 (enExample) |
| EP (1) | EP3374368B1 (enExample) |
| JP (1) | JP6892859B2 (enExample) |
| CN (1) | CN108602848B (enExample) |
| CA (1) | CA3000924A1 (enExample) |
| ES (1) | ES2921500T3 (enExample) |
| WO (1) | WO2017080973A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018011094A1 (en) * | 2016-07-12 | 2018-01-18 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| EP3621973A4 (en) | 2017-05-12 | 2021-10-27 | Galectin Sciences, LLC | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND THEIR USE |
| US12227567B2 (en) | 2017-07-25 | 2025-02-18 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| US11072626B2 (en) | 2017-10-11 | 2021-07-27 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| WO2019133878A1 (en) | 2017-12-29 | 2019-07-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
| EP3807290B1 (en) | 2018-06-15 | 2022-03-30 | Bristol-Myers Squibb Company | Tetrahydropyran-based thiodisaccharide mimics as galectin-3 inhibitors |
| CN113166122A (zh) | 2018-12-06 | 2021-07-23 | 百时美施贵宝公司 | 半乳糖凝集素-3的小分子抑制剂 |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| EP3902797A1 (en) | 2018-12-27 | 2021-11-03 | GlycoMimetics, Inc. | Galectin-3 inhibiting c-glycosides |
| EP3918323A4 (en) | 2019-01-30 | 2022-12-28 | TrueBinding, Inc. | ANTI-GAL3 ANTIBODIES AND THEIR USES |
| WO2021081881A1 (zh) * | 2019-10-31 | 2021-05-06 | 深圳先进技术研究院 | 一种基于tdg分子骨架的功能糖类分子及其制备方法 |
| CN113521283A (zh) * | 2020-04-14 | 2021-10-22 | 中国医学科学院药物研究所 | Galectin-3作为靶标在寻找保护胰岛功能药物或者生物制剂中的应用 |
| JP7705884B2 (ja) | 2020-05-05 | 2025-07-10 | ブリストル－マイヤーズ スクイブ カンパニー | ガレクチン－３の低分子阻害剤 |
| US12286424B2 (en) | 2020-05-11 | 2025-04-29 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| CA3185040A1 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| KR20230018431A (ko) | 2020-05-28 | 2023-02-07 | 브리스톨-마이어스 스큅 컴퍼니 | 갈렉틴-3 억제제 |
| WO2022171561A1 (en) * | 2021-02-10 | 2022-08-18 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) * | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| CN102066393B (zh) * | 2008-05-16 | 2014-07-02 | 格莱克特生物技术公司 | 半乳糖苷抑制剂的合成 |
| WO2010126435A1 (en) | 2009-04-28 | 2010-11-04 | Forskarpatent I Syd Ab | Novel galactoside inhibitors of galectins |
| ES2698101T3 (es) | 2012-10-10 | 2019-01-31 | Galectin Therapeutics Inc | Compuestos de carbohidrato con restos de galactosa para el tratamiento de la nefropatía diabética y trastornos asociados |
| ES2817888T3 (es) * | 2012-10-31 | 2021-04-08 | Galecto Biotech Ab | Inhibidor de galactósido de galectina-3 y su uso para tratar fibrosis pulmonar |
| WO2014078655A1 (en) * | 2012-11-15 | 2014-05-22 | Tufts University | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor |
| EP3415522A1 (en) * | 2014-07-09 | 2018-12-19 | Galecto Biotech AB | Novel hybrid galactoside inhibitor of galectins |
| US10464964B2 (en) | 2015-01-16 | 2019-11-05 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| EP3828191A3 (en) | 2015-01-30 | 2021-08-18 | Galecto Biotech AB | Novel galactoside inhibitor of galectins |
-
2016
- 2016-11-08 CA CA3000924A patent/CA3000924A1/en active Pending
- 2016-11-08 EP EP16794292.9A patent/EP3374368B1/en active Active
- 2016-11-08 CN CN201680076549.6A patent/CN108602848B/zh not_active Expired - Fee Related
- 2016-11-08 ES ES16794292T patent/ES2921500T3/es active Active
- 2016-11-08 WO PCT/EP2016/076918 patent/WO2017080973A1/en not_active Ceased
- 2016-11-08 JP JP2018523432A patent/JP6892859B2/ja not_active Expired - Fee Related
- 2016-11-08 US US15/774,868 patent/US10730902B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534301A5 (enExample) | ||
| JP6342805B2 (ja) | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2016526540A5 (enExample) | ||
| JP2019510787A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| RU2012151012A (ru) | Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием | |
| JP2016531126A5 (enExample) | ||
| JP2011523412A5 (enExample) | ||
| JP2017506666A5 (enExample) | ||
| RU2016115803A (ru) | Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний | |
| EA201590624A1 (ru) | Циклические эфиры пиразол-4-ил-гетероциклил-карбоксамидных соединений и способы их применения | |
| JP2020510054A5 (enExample) | ||
| JP2017507122A5 (enExample) | ||
| NZ627750A (en) | Carbamate compounds and of making and using same | |
| JP2013509431A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| JP2020520957A5 (enExample) | ||
| CN107151250B (zh) | 嘧啶类七元环化合物、其制备方法、药用组合物及其应用 | |
| JP2017534591A5 (enExample) | ||
| JP2013523814A5 (enExample) | ||
| CN112771045A (zh) | 喹啉并吡咯烷-2-酮类衍生物及其应用 | |
| RU2017141561A (ru) | Производные тетрагидронафтиридинилпропионовой кислоты и их применение | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения |